Planet Briefing

First published · Last updated

P2.02.15 Drug Tolerance and Persistence to EGFR Inhibitor Treatment Are Mediated by an ILK-SFK-YAP Signaling Axis in Lung Adenocarcinoma

Journal article (Publisher: Elsevier BV) reporting that drug tolerance and persistence to EGFR inhibitor treatment in lung adenocarcinoma are mediated by an ILK-SFK-YAP signaling axis. The source provided is a journal article entry published 2025-10-01.

Fig 10. Response of EGFR ΔELREA mutant lung cancer cells to tyrosine kinase inhibitors. Sensitivity (cell survival versus inhibitor concentration) of lung cancer cell lines harboring EGFR ΔELREA mutant (red curves) versus wild-type EGFR (black curves) to (A) erlotinib, (B) gefitinib, (C) afatinib, and (D) lapatinib. The data were collected from the publicly available databases CCLE, CTRP and GDSC, as indicated.
Illustrative image: Fig 10. Response of EGFR ΔELREA mutant lung cancer cells to tyrosine kinase inhibitors. Sensitivity (cell survival versus inhibitor concentration) of lung cancer cell lines harboring EGFR ΔELREA mutant (red curves) versus wild-type EGFR (black curves) to (A) erlotinib, (B) gefitinib, (C) afatinib, and (D) lapatinib. The data were collected from the publicly available databases CCLE, CTRP and GDSC, as indicated. — Tamirat MZ, Koivu M, Elenius K, Johnson MS/Wikimedia Commons, CC BY 4.0

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
6/10
Geographic reach
1/10
Global importance
3/10
Impact magnitude
3/10
Positivity
7/10
Urgency
2/10

Why it matters

The article presents a described molecular mechanism underlying drug tolerance in lung adenocarcinoma treatment.

Sources

Report an issue